Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice

Journal of Pharmaceutical Sciences

Volumn 92, Issue 8, 2003, Pages 1665-1676

  Lobo, Evelyn D ^a   Soda, David M ^a   Balthasar, Joseph P ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Agonistic effect; Antagonistic effect; Anti drug antibodies; Methotrexate

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; METHOTREXATE; METHOTREXATE ANTIBODY; MONOCLONAL ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; COMPUTER SIMULATION; CONTROLLED STUDY; KINETICS; MALE; MORTALITY; MOUSE; NONHUMAN; PHARMACODYNAMICS; TOXICITY; WEIGHT REDUCTION;

EID: 0041709263     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10432     Document Type: Article

References (27)

1. Balthasar JP, Fung HL. 1994. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: Studies using digoxin as a model drug. J Pharmacol Exp Ther 268:734-739.
2. Balthasar JP, Fung HL. 1996. Inverse targeting of peritoneal tumors: Selective alteration of the disposition of methotrexate through the use of antimethotrexate antibodies and antibody fragments. J Pharm Sci 85:1035-1043.
3. Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR. 1993. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717-2723.
4. May LT, Neta R, Moldawer LL, Kenney JS, Patel K, Sehgal PB. 1993. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol 151:3225-3236.
5. Faulstich H, Kirchner K, Derenzini M. 1988. Strongly enhanced toxicity of the mushroom toxin alpha-amanitin by an amatoxin-specific Fab or monoclonal antibody. Toxicon 26:491-499.
6. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. 1996. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697-1702.
7. Pimm MV, Caten JE, Clegg JA, Jacobs E, Baldwin RW. 1987. Comparative biodistribution of methotrexate and monoclonal antibody-methotrexate complexes in mice. J Pharm Pharmacol 39:764-767.
8. Holton OD III, Black CD, Parker RJ, Covell DG, Barbet J, Sieber SM, Talley MJ, Weinstein JN. 1987. Biodistribution of monoclonal IgG1, F(ab′)2, and Fab′ in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J Immunol 139: 3041-3049.
9. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. 1986. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′ in mice. Cancer Res 46:3969-3978.
10. Balthasar JP, Fung HL. 1995. High-affinity rabbit antibodies directed against methotrexate: Production, purification, characterization, and pharmacokinetics in the rat. J Pharm Sci 84:2-6.
11. Harlow E, Lane D. 1988. Antibodies: A laboratory manual. New York: Cold Spring Harbor Laboratory.
12. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide: Pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: Biomedical Simulations Resource.
13. Khan AA, Slifer TR, Araujo FG, Suzuki Y, Remington JS. 2000. Protection against lipopolysaccharide-induced death by fluoroquinolones. Antimicrob Agents Chemother 44:3169-3173.
14. Smith TW, Haber E, Yeatman L, Butler VP Jr. 1976. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 294:797-800.
15. Sabouraud A, Urtizberea M, Grandgeorge M, Gattel P, Makula ME, Scherrmann JM. 1991. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. Toxicology 68:121-132.
16. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM. 1996. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278:709-716.
17. Sullivan JB Jr. 1987. Past, present, and future immunotherapy of snake venom poisoning. Ann Emerg Med 16:938-944.
18. Teng NN, Kaplan HS, Hebert JM, Moore C, Douglas H, Wunderlich A, Braude AI. 1985. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc Natl Acad Sci USA 82:1790-1794.
19. Morelli D, Menard S, Cazzaniga S, Colnaghi MI, Balsari A. 1997. Intratibial injection of an antidoxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice. Br J Cancer 75:656-659.
20. Sardini A, Villa E, Morelli D, Ghione M, Menard S, Colnaghi MI, Balsari A. 1992. An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. Int J Cancer 50:617-620.
21. Balsari AL, Morelli D, Menard S, Veronesi U, Colnaghi MI. 1994. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 8:226-230.
22. Kroll RA, Pagel MA, Langone JJ, Sexton GJ, Neuwelt EA. 1994. Differential permeability of the blood-tumour barrier in intracerebral tumour-bearing rats: Antidrug antibody to achieve systemic drug rescue. Ther Immunol 1:333-341.
23. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. 1993. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235-1244.
24. Quezado ZM, Natanson C, Alling DW, Banks SM, Koev CA, Elin RJ, Hosseini JM, Bacher JD, Danner RL, Hoffman WD. 1993. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA 269:2221-2227.
25. Crom WR, Evans WE. 1992. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring, 3rd ed. Vancouver: Applied Therapeutics. pp 2912-2913.
26. Pinedo HM, Chabner BA. 1977. Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 61:709-715.
27. Ramanathan M. 1996. A pharmacokinetic approach for evaluating cytokine binding macromolecules as antagonists. Pharm Res 13:84-90.